Has Ana-Maria Orbai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $89,051 in general payments to Ana-Maria Orbai, MD across 74 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ana-Maria Orbai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ana-Maria Orbai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ana-Maria Orbai, MD

Internal Medicine · Baltimore, MDNPI 1255516332

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $65,861 of the $89,051 with a category attached, or 74.0%. 9 manufacturers reported payments, led by Novartis at 30.9% of the total. Reporting peaked in 2019 at $52,675 and has fallen 97.3% since, to $1,442 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,051in general payments, 2019–2025

Across 74 payments — averaging $1203.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$28K
Janssen Scientific Affairs, LLC$15K
Eli Lilly$15K
UCB SA$11K
Johnson & Johnson$10K
Pfizer$6K
plus $5K from 3 others

$1,065,242in research payments, 2019–2025

Across 128 payments — averaging $8322.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$378K
Amgen$350K
Janssen Research & Development, LLC$190K
Gilead$45K
Takeda Pharmaceuticals U.S.A., Inc.$45K
Eli Lilly$27K
plus $31K from 2 others

What the payments were for

Consulting fees$65,86174%
Speaking & faculty fees$6,4007%
Travel & lodging$15,24017%
Food & beverage$1,5512%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	21	$27,509
Janssen Scientific Affairs, LLC	8	$15,331
Eli Lilly	7	$14,766
UCB SA	16	$10,926
Johnson & Johnson	9	$9,548
Pfizer	2	$6,400
E.r. Squibb & Sons, L.L.C.	1	$2,112
Takeda Pharmaceuticals U.S.A., Inc.	9	$1,357
Sanofi	1	$1,102

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$24,665
COSENTYX$20,941
TALTZ$14,545
XELJANZ$6,400
ILARIS$5,517
SIMPONI ARIA$4,600
STELARA$4,600
REMICADE$4,600
Bimzelx$3,960
KEVZARA$1,102
DIOVAN$643

How this compares

$89,051 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland →

Medicare billing

Part B allowed, 2024

$29,432

Medicare patients

123

Services billed

348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab	37	$441,847
Skyrizi PenRisankizumab-Rzaa	17	$334,752
RinvoqUpadacitinib	41	$256,750
Cosentyx Sensoready PenSecukinumab	18	$212,661
Enbrel SureclickEtanercept	24	$195,200
Humira PenAdalimumab	16	$171,398
OtezlaApremilast	30	$155,494
Humira(Cf) PenAdalimumab	16	$120,711
Enbrel MiniEtanercept	11	$94,899
RasuvoMethotrexate/Pf	11	$10,535
MethotrexateMethotrexate Sodium	59	$2,873
Leflunomide	26	$1,641
Hydroxychloroquine Sulfate	13	$1,296
Sulfasalazine DrSulfasalazine	28	$1,156
Prednisone	22	$200

Paid to pharmacies, not to this prescriber.

Other internal medicine in Baltimore

Param DedhiaBaltimore$636K
Shawn DhillonBaltimore$227K
Jeremy SugarmanBaltimore$210K
Charles FlexnerBaltimore$133K
Kristen MarroneBaltimore$97K
Mark YarchoanBaltimore$89K
David Muniz PedrogoBaltimore$82K
Julie PaikBaltimore$76K
Allison AgwuBaltimore$58K
Jeffrey ThiboutotBaltimore$57K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →